|
Clinically Important Changes in Rheumatoid Arthritis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Clinically Important Changes in Rheumatoid Arthritis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Clinically Important Changes in Rheumatoid Arthritis Clinical research trials and Clinically Important Changes in Rheumatoid Arthritis health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Clinically Important Changes in Rheumatoid Arthritis. Clinically Important Changes in Rheumatoid Arthritis Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Clinically Important Changes in Rheumatoid Arthritis clinical trial. Participants oftentimes recieve the most expert healthcare available for their Clinically Important Changes in Rheumatoid Arthritis condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinically Important Changes in Rheumatoid Arthritis  Clinically Important Changes in Rheumatoid Arthritis
Clinically Important Changes in Rheumatoid Arthritis
For Condition: Rheumatoid Arthritis
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study will explore how patients with rheumatoid arthritis evaluate, or rate, symptom improvements. Physicians generally evaluate patients' health and treatment benefits based on laboratory measures, such as the number of tender or swollen joints, duration of morning stiffness, grip strength, pain severity and others. Less attention is given to whether these treatment results are meaningful to patients. This study will examine how much of an improvement in pain, stiffness, function, and other symptoms is needed before patients consider the change an important improvement. Patients 18 years of age or older who were diagnosed with rheumatoid arthritis after age 16 and who have active arthritis (6 or more tender joints) may be eligible for this study. Of particular interest are patients beginning treatment with prednisone, methotrexate, leflunomide, infliximab, or etanercept, although patients receiving any type of treatment may be included. Participants will be evaluated twice at the NIH Clinical Center, once at the start of the study and again at either 1 month or 4 months later, depending on the individual's treatment regimen. Permission will also be requested to review patients' medical records for results of previous blood tests and x-rays. At each NIH visit, patients will undergo the following tests and procedures: - Medical history and physical examination, including evaluation of joint swelling and tenderness; - Questionnaires about rheumatoid arthritis symptoms; - Computer-based exercise to assess preferences for various state-of-health choices; - Grip strength test; - Walking test on level ground, with or without the use of a cane or walker; - Blood test to measure inflammation. At the second visit, in addition to the above procedures, participants will complete a questionnaire to rate the importance of changes, if any, in pain, morning stiffness, fatigue, joint swelling, functioning, worry, depression, and overall impressions, since the first visit.
Details: Proper interpretation of the results of clinical trials requires an assessment of not only the statistical significance of treatment differences but also the clinical importance of such differences. Efforts to define criteria for important improvement in rheumatoid arthritis (RA) activity have thus far not considered the patient's perspective. The aim of this project is to determine if criteria for important improvement in arthritis activity measures can be defined. This will be done by assessing the agreement among patients of judgments of important changes in arthritis activity. We will also determine if preference measures, which are a group of measures of the desirability of a particular state of health, can be used to assess when patients experience an important change in their arthritis. This prospective longitudinal observational study will measure changes in 12 arthritis activity measures, changes in preference measures, and judgments of the importance of changes in arthritis activity over one to four months in 300 patients with active RA. Consensus among patients regarding the degree of change considered important would allow group criteria for important improvement to be defined that were based on patients' valuations.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Participants will be recruited by physician referral and self-referral. Inclusion criteria will be: 1. A diagnosis of RA; 2. Age 18 years or older; 3. Onset of arthritis after the age of 16 years; 4. English literacy; 5. Active arthritis, as evidence by six or more tender joints. EXCLUSION CRITERIA: Exclusion criteria will be: 1. Inability to provide informed consent. 2. Children will necessarily be excluded from this protocol.
Total Enrollment: 300
Location and Contact Information:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030133; 03-AR-0133
Study Start Date: March 17, 2003
Record last reviewed: January 14, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056602
Other Rheumatoid Arthritis Studies:
1. A multi-center trial to compare the efficacy and safety of three doses of Meloxicam and placebo in patients with Rheumatoid Arthritis.
2. dnaJ Peptide for Relieving Rheumatoid Arthritis
3. Study to Assess Efficacy of Tacrolimus + Methotrexate Vs. Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
4. Efficacy & Safety of an Investigational Drug + Methotrexate Compared to Methotrexate Alone in Patients with Rheumatoid Arthritis
5. 3 Different Dose Levels Of CCI-779 In Subjects With Active Rheumatoid Arthritis On Concomitant Methotrexate Therapy
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Clinically Important Changes in Rheumatoid Arthritis
|
|
|
|
|
|
|
|
